According to filings with the U.S. Securities and Exchange Commission, Inflammasome Therapeutics is raising $3,796,600.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Paul Ashton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inflammasome Therapeutics
Inflammasome Therapeutics is a science based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson’s disease. The precise causes of these diseases are unknown, however, they share many of the same risk factors, such as, smoking, obesity, hypertension, and age. They all are multifactorial diseases with multiple biochemical factors, many shared, contributing to their progression. It is now recognized that these diseases are all characterized by upregulation of the inflammatory process, driven by prolonged activation of inflammasomes. Inflammasomes are intracellular multiprotein complexes that help trigger and maintain the inflammatory response normally as part of the innate immune system. However, in Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson’s disease, inflammasomes become chronically activated, causing the continual release of inflammatory elements such as caspase-1, IL-18, and IL-1, which in turn cause progressive tissue damage and disease progression. Inflammasome Therapeutics’ focus is on reducing the dysregulation of the inflammatory process by preventing aberrant inflammasome activation.

To learn more about Inflammasome Therapeutics, visit http://www.inflam.com

Contact:
Paul Ashton, Chief Executive Officer
617-331-1071

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.